ArticleJournal of clinical practice and research2026
Endothelial Biomarkers Predict Clinical Deterioration in Acute Pancreatitis.
Article in Journal of clinical practice and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Endothelial dysfunction contributes to the severity of acute pancreatitis (AP), but the prognostic utility of endothelial biomarkers and their association with therapeutic interventions remain poorly defined. This study aimed to determine whether endothelial dysfunction biomarkers predict clinical deterioration in AP and whether plasmapheresis is associated with changes in these biomarkers and clinical outcomes. Materials and Methods: In this prospective cohort study of 100 patients with AP, serial endothelial biomarkers, including vascular endothelial growth factor (VEGF), von Willebrand factor (vWF), endothelin-1 (ET-1), and soluble E-selectin (sE-selectin), were measured on admission and on days 3 and 7. All patients received conventional therapy, and 68 additionally received adjunctive plasmapheresis through nonrandomized assignment. The conventional therapy cohort (n=32) was stratified into Worsened (n=17) and Improved (n=15) subgroups according to clinical course to establish prognostic biomarker cutoffs. Results: Endothelial marker levels at admission predicted subsequent clinical deterioration (p<0.001). Biomarker trajectories differed significantly between the Improved and Worsened subgroups. Patients who received plasmapheresis exhibited more favorable biomarker profiles, with levels resembling those of the Improved subgroup by day 7. This biomarker pattern was associated with a lower rate of the composite clinical deterioration endpoint than that observed in the Worsened subgroup (12% vs. 100%, p<0.001). Conclusion: Endothelial dysfunction biomarkers are early predictors of the clinical course of AP. Plasmapheresis was associated with favorable biomarker trajectories and improved clinical outcomes, suggesting that endothelial dysfunction may be a potential therapeutic target warranting investigation in randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.